Overview

A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome

Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
Netherton Syndrome (NS) is a severe rare disease characterized by generalized scaling, erythema, and epidermal barrier defects. This study assessed the safety, pharmacokinetics (PK), and efficacy of DS-2325a in patients with NS.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Daiichi Sankyo